YOLFTbeta
OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc.

OKUR · NASDAQ · Healthcare / Biotechnology

2.63USD-0.38 (-12.62%)

Price History

Full chart

Market Stats

Previous Close3.01
Open3.03
Day Range2.60 – 3.08
52-Week Range2.23 – 5.38
Volume891.35K
Market Cap111.77M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.88
Dividend Yield0.00%
50-Day Avg3.68
200-Day Avg3.68

About

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Nicholas A. Saccomano Ph.D.
  • Employees45
  • Headquarters6707 Winchester Circle, Boulder, CO, United States, 80301, USA
  • Websitehttps://onkuretherapeutics.com

Leadership

  • Dr. Nicholas A. Saccomano Ph.D.President, CEO & Director · b. 1959
  • Mr. Jason A. Leverone CPAChief Financial Officer · b. 1974
  • Dr. Samuel Agresta M.D., M.P.H.Chief Medical Officer · b. 1973
  • Dr. Dylan Hartley Ph.D.Chief Scientific Officer · b. 1969
  • Mr. Rogan P. Nunn J.D.General Counsel & Secretary
  • Dr. James Blake Ph.D.Senior Vice President of Computational Drug Discovery
  • Dr. Kevin S. Litwiler Ph.D.Senior Vice President of DMPK & Clinical Pharmacology
  • Dr. Mark L. Boys Ph.D.Senior Vice President of Discovery Chemistry
  • Ms. Roberta AltonSenior Vice President of Clinical Operations

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0000
Cost of Revenue37.00K50.00K529.00K560.00K662.00K830.00K
Gross Profit-37.00K-50.00K-529.00K-560.00K-662.00K-830.00K
Operating Expense19.52M39.77M29.24M36.37M53.72M62.12M
Operating Income-19.55M-39.82M-29.77M-36.93M-54.39M-62.95M
EBITDA-19.43M-39.72M-29.13M-34.75M-51.71M-58.69M
Net Income-19.46M-39.77M-29.51M-35.31M-52.67M-59.52M
R&D15.91M28.12M25.86M32.12M43.80M48.26M
Interest Expense---0300.00K8.00K

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets55.22M154.02M16.00M35.73M114.91M62.12M
Total Liabilities97.34M6.81M70.42M137.58M11.08M5.93M
Total Equity-42.12M147.21M-54.42M-101.84M103.83M56.18M
Cash53.61M124.66M11.54M29.88M110.76M59.05M
Total Debt92.72M-637.00K674.00K1.08M549.00K
Net Debt39.11M-124.66M-10.91M-29.20M-109.68M-58.50M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-18.54M-37.98M-26.95M-34.55M-51.12M-51.83M
Investing Cash Flow7.38M-23.38M-1.13M-246.00K15.87M-46.00K
Financing Cash Flow47.27M132.41M26.46M53.13M116.13M163.00K
Capital Expenditure24.00K198.00K1.13M246.00K52.00K46.00K
Free Cash Flow-18.56M-38.18M-28.09M-34.79M-51.17M-51.87M
FCF to OCF100.13%100.52%104.21%100.71%100.10%100.09%

Earnings

Report DateMay 20, 2021Aug 11, 2021Nov 12, 2021Mar 24, 2022May 11, 2022Aug 9, 2022Nov 8, 2022Mar 27, 2023May 11, 2023Aug 10, 2023Nov 13, 2023Mar 28, 2024May 7, 2024Aug 13, 2024Nov 7, 2024Mar 10, 2025May 5, 2025Aug 12, 2025Nov 6, 2025Mar 13, 2026May 5, 2026Aug 4, 2026Nov 5, 2026
EPS Estimate---------------0.90-0.87-1.38-1.25-1.20-1.15-0.74-0.58-0.35
EPS Actual-2.97-4.31-5.22-4.34-5.33-5.03-5.31-5.54-6.03-6.46-5.68-7.05-2.52-1.60-0.86-1.37-1.19-1.14-1.09-0.99-1.11-0.31-
Surprise--------------4.44%-57.47%14.04%8.80%9.17%14.06%-50.00%46.55%-
Timing--------------After-hoursAfter-hoursPre-marketAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap111.77M
Enterprise Value-54.38M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.69
EPS-2.88
Book Value4.25
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-61.74M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-46.91%
Return on Assets-29.26%
Shares Outstanding40.50M
Shares Float21.38M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 15.50
  • Strong Buy
    5
  • Buy
    1

Ownership Breakdown

Institutions
87.25%
Insiders
10.45%
Retail / Other
2.30%

Top Institutional Holders

  • RA Capital Management, LLC
    4.00M9.87%
  • StepStone Group LLC
    2.66M6.57%
  • ADAR1 Capital Management LLC
    2.43M6.01%
  • Bvf Inc
    1.98M4.89%
  • Vivo Capital, LLC
    1.93M4.76%
  • Vestal Point Capital LP
    1.84M4.54%
  • Trails Edge Capital Partners, LP
    1.44M3.55%
  • Adage Capital Partners Gp LLC
    1.20M2.98%
  • Citadel Advisors Llc
    1.19M2.93%
  • Sio Capital Management, LLC
    1.08M2.66%
  • Prosight Management, LP
    978.99K2.42%
  • Logos Global Management LP
    963.86K2.38%
  • Vanguard Capital Management, LLC
    582.48K1.44%
  • NEA Management Company, LLC
    478.55K1.18%
  • Rosalind Advisors, Inc.
    443.76K1.10%
  • Renaissance Technologies Corp
    377.25K0.93%
  • The Carlyle Group Inc
    269.89K0.67%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.15M2.85%
  • iShares Russell 2000 ETF
    560.52K1.38%
  • Fidelity Small Cap Index
    283.54K0.70%

Stock Splits

  • Oct 7, 20241:10